ライフサイエンスコーパス: valvular heart disease

1 uideline for the Management of Patients With Valvular Heart Disease".

2 ry disease, 20% atrial fibrillation, and 17% valvular heart disease).

3 newer options for diagnosis and treatment of valvular heart disease.

4 l for identifying compounds likely to induce valvular heart disease.

5 idelines for the Management of Patients With Valvular Heart Disease.

6 echanism for development of the drug-induced valvular heart disease.

7 ercutaneous approaches for the correction of valvular heart disease.

8 gold standard for treatment of patients with valvular heart disease.

9 en a concordant decline in the prevalence of valvular heart disease.

10 heir development of effective treatments for valvular heart disease.

11 ive endocarditis in patients with underlying valvular heart disease.

12 pathway may play a role in the mechanism for valvular heart disease.

13 ge, body mass index, smoking, and history of valvular heart disease.

14 ogenesis are important in the development of valvular heart disease.

15 ike to be the ultimate solution for treating valvular heart disease.

16 alve matrix architecture that are evident in valvular heart disease.

17 tion, carcinoid tumors can cause right-sided valvular heart disease.

18 until it was reported to be associated with valvular heart disease.

19 weight loss may be associated with increased valvular heart disease.

20 receiving fenfluramine-phentermine developed valvular heart disease.

21 mmon type of inducible SMVT in patients with valvular heart disease.

22 Users of diet medications are at risk for valvular heart disease.

23 ssed the issue of longitudinal assessment of valvular heart disease.

24 e-phentermine therapy may be associated with valvular heart disease.

25 ffects, including pulmonary hypertension and valvular heart disease.

26 reasing recognition of nonrheumatic forms of valvular heart disease.

27 20 years have transformed the management of valvular heart disease.

28 siderably less attention than other forms of valvular heart disease.

29 proteomics, and metabolomics to the study of valvular heart disease.

30 scuss how these structures change in primary valvular heart disease.

31 t molecular pathways contributing to primary valvular heart disease.

32 vular heart diseases, and 30 (3.2%) isolated valvular heart disease.

33 vein graft remodeling, atherosclerosis, and valvular heart disease.

34 l heart disease, pulmonary hypertension, and valvular heart disease.

35 ilated left ventricular cardiomyopathies and valvular heart disease.

36 f coronary artery disease, hypertension, and valvular heart disease.

37 tions than previously appreciated, including valvular heart disease.

38 and quality of echocardiographic studies for valvular heart disease.

39 newer options for diagnosis and treatment of valvular heart disease.

40 clerosis, myocardial infarction, stroke, and valvular heart disease.

41 ociated with improved concordance in grading valvular heart disease.

42 ccredited laboratories for the evaluation of valvular heart disease.

43 s (289 male, 67+/-10 years) with ischemic or valvular heart disease.

44 Aortic stenosis is the most frequent valvular heart disease.

45 nowledge for the management of patients with valvular heart disease.

46 ion, and research in the field of structural valvular heart disease.

47 cardiomyopathy, ischemic heart disease, and valvular heart disease.

48 is that selective 5-HT2C agonism would avoid valvular heart disease.

49 heter therapies are being developed to treat valvular heart disease.

50 Aortic stenosis is the most common form of valvular heart disease.

51 ost challenging encountered in patients with valvular heart disease.

52 re more likely to have history of stroke and valvular heart disease.

53 guidance, and post-procedural assessment of valvular heart disease.

54 ntional surgery in the treatment of acquired valvular heart disease.

55 ic dysfunction, diastolic abnormalities, and valvular heart disease.

56 aortic stenosis is the most prevalent of all valvular heart diseases.

57 important treatment option for patients with valvular heart diseases.

58 urgitation (MR) is one of the most prevalent valvular heart diseases.

59 CV disease, heart failure, arrhythmias, and valvular heart diseases.

60 art disease, 1.07 (95% CI, 0.89 to 1.30) for valvular heart disease, 1.07 (95% CI, 0.96 to 1.19) for

61 rs & Thromboembolism, Vascular Medicine, and Valvular Heart Disease.(1-100).

62 ion, Rhythm Disorders & Thromboembolism, and Valvular Heart Disease.(1-100).

63 a; Rhythm Disorders and Thromboembolism; and Valvular Heart Disease.(1-104) * To view the full manusc

64 on for ischemic heart disease (9.9% v 9.7%), valvular heart disease (2.9% v 2.8%), conduction abnorma

65 mic heart disease (410-414, 36.0, and 36.1), valvular heart disease (394-397, 424, 35), congestive he

66 4%), pulmonary vascular disease (1.2%-7.1%), valvular heart disease (5.0%-9.8%), and renal failure (7

67 (0 of 3 patients) vs those without multiple valvular heart disease (6 of 8 patients [75.0%]) and in

68 ysplasia (ARVD, 17%), postmyocarditis (14%), valvular heart disease (8%), congenital heart disease (2

69 were being evaluated for stable angina (53), valvular heart disease (8), atypical chest pain (12), or

70 tic stenosis (AS) is the most common form of valvular heart disease, affecting 2% of those over age 6

71 coronary artery disease (aHR, 1.051.151.27), valvular heart disease (aHR, 1.221.321.43), peripheral v

72 al advances is providing unique solutions to valvular heart disease also requiring revascularization,

73 al therapeutic molecular targets for primary valvular heart disease and discuss key knowledge gaps th

74 itial association between the development of valvular heart disease and drugs stems from observations

75 eart disease, arrhythmia, heart failure, and valvular heart disease and formulate practice-based reco

76 Aortic stenosis (AS) is a common valvular heart disease and has no pharmacological therap

77 our understanding of the pathophysiology of valvular heart disease and in the surgical techniques fo

78 Background Valvular heart disease and intracardiac shunts can disru

79 of the atrium is described in patients with valvular heart disease and is associated with an increas

80 Mitral regurgitation (MR) is a common valvular heart disease and is the second most frequent i

81 y common and unexpected finding in end-stage valvular heart disease and may be associated with repair

82 ngs advance our understanding of this common valvular heart disease and may reveal novel therapeutic

83 t be explained by ischemic, hypertensive, or valvular heart disease and often results in sudden cardi

84 y multivariate analyses, in subjects free of valvular heart disease and preexisting cardiovascular di

85 Mitral regurgitation (MR) is the most common valvular heart disease and presents unique challenges fo

86 view of the current and future management of valvular heart disease and propose treatment approaches

87 Furthermore, comorbidities such as valvular heart disease and renal failure as well as an e

88 emonstrates that the Lewis rat is a model of valvular heart disease and that streptococcal M protein

89 une responses against cardiac myosin lead to valvular heart disease and the infiltration of the heart

90 ady been undertaken to inhibit EndMT in both valvular heart disease and vein graft remodeling, with p

91 ral regurgitation (MR) is the most prevalent valvular heart disease and, when left untreated, it conf

92 ase, diabetes mellitus, atrial fibrillation, valvular heart disease, and antihypertensive medication

93 ute excess risks for ischemic heart disease, valvular heart disease, and cardiomyopathy.

94 rest in establishing best practices in TAVR, valvular heart disease, and cardiovascular implantable e

95 an emphasis on nonischemic cardiomyopathies, valvular heart disease, and COVID-19 disease cardiac man

96 istory of atrial fibrillation, hypertension, valvular heart disease, and hypercholesterolemia.

97 ting factors, such as renal artery stenosis, valvular heart disease, and ischemia, should be strongly

98 ase including metabolic syndrome, left-sided valvular heart disease, and ischemic heart disease are c

99 Mitral regurgitation (MR) is the most common valvular heart disease, and mitral valve surgery is the

100 xperts, including reduced ejection fraction, valvular heart disease, and other cardiomyopathies.

101 as chest pain, congestive heart failure, and valvular heart disease, and preoperative risk assessment

102 ardial infarction, congestive heart failure, valvular heart disease, and stroke or transient ischemic

103 erial revascularization, rheumatic and other valvular heart disease, and symptomatic bradyarrhythmia;

104 tions are now available for the treatment of valvular heart disease, and their efficacy and safety ha

105 vention, Rhythm Disorders & Thromboembolism, Valvular Heart Disease, and Vascular Medicine (1-100).

106 tabolic & Lipid Disorders, Rhythm Disorders, Valvular Heart Disease, and Vascular Medicine (1-100).

107 vention, Rhythm Disorders & Thromboembolism, Valvular Heart Disease, and Vascular Medicine (1-100).

108 ders & Lipids, Rhythm Disorders, Statistics, Valvular Heart Disease, and Vascular Medicine (1-63).

109 tabolic & Lipid Disorders, Rhythm Disorders, Valvular Heart Disease, and Vascular Medicine (1-84).

110 urodegenerative Disorders, Rhythm Disorders, Valvular Heart Disease, and Vascular Medicine (1-86).

111 tabolic & Lipid Disorders, Rhythm Disorders, Valvular Heart Disease, and Vascular Medicine.

112 ders & Lipids, Rhythm Disorders, Statistics, Valvular Heart Disease, and Vascular Medicine.

113 urodegenerative Disorders, Rhythm Disorders, Valvular Heart Disease, and Vascular Medicine.

114 The role of diabetes in the development of valvular heart disease, and, in particular, the relation

115 fects, 80 (8.5%) simultaneous congenital and valvular heart diseases, and 30 (3.2%) isolated valvular

116 ease, or Group 2 PH, includes heart failure, valvular heart diseases, and congenital heart diseases.

117 l similarities between coronary and calcific valvular heart disease (aortic stenosis [AS] and mitral

118 and comorbidities such as renal failure and valvular heart disease are independent predictors for AF

119 herapeutic options for calcific vascular and valvular heart disease are invasive transcatheter proced

120 Valvular heart diseases are not usually regarded as a ma

121 myopathy, while the main divergences were in valvular heart disease, arrhythmias, and aortic disease.

122 holds immense potential for the treatment of valvular heart disease as adjuncts to surgical intervent

123 rticle reviews unique advantages emerging in valvular heart disease as the technology of invasive car

124 ations for clinicians to diagnose and manage valvular heart disease as well as supporting documentati

125 s less frequent in patients who had multiple valvular heart disease before TAVI (0 of 3 patients) vs

126 mended first-line test for the assessment of valvular heart disease, but cardiovascular magnetic reso

127 es have much promise as biomarkers in common valvular heart disease, but the impact of their measurem

128 third-degree atrioventricular block, severe valvular heart disease, cardiomyopathy, and pulmonary or

129 lve stenosis (AVS), which is the most common valvular heart disease, causes a progressive narrowing o

130 cardiomyopathy, hypertensive heart disease, valvular heart disease, cerebrovascular disease or nonca

131 remained underrepresented in North American valvular heart disease clinical trials.

132 e models, the use of diuretics, a history of valvular heart disease, coronary disease, advancing age,

133 An echocardiographic carcinoid valvular heart disease (CVHD) % score was determined fro

134 VD subtypes increased; however, the trend of valvular heart disease decreased.

135 African American, and to have hypertension, valvular heart disease, diabetes, hypothyroidism, AIDS,

136 olesterol; history of myocardial infarction, valvular heart disease, diabetes, lung disease, and use

137 sociation between patient factors and missed valvular heart disease diagnoses.

138 m surrounding the diagnosis and treatment of valvular heart disease, driven in part by emerging percu

139 Valvular heart disease due to congenital abnormalities o

140 In this first study of EPNs for valvular heart disease, EPNs increased rates of AVR for

141 been the standard of care for patients with valvular heart disease for many decades, but transcathet

142 American College of Cardiology guidelines on valvular heart disease generated considerable controvers

143 This executive summary of the valvular heart disease guideline provides recommendation

144 c disease guideline and Section 5.1.3 of the valvular heart disease guideline.

145 Many recommendations from the earlier valvular heart disease guidelines have been updated with

146 cture: Many recommendations from the earlier valvular heart disease guidelines have been updated with

147 patients (52.6% of those with congenital or valvular heart disease) had received corrective cardiac

148 As populations age worldwide, the burden of valvular heart disease has grown exponentially, and so h

149 The incidence of congenital valvular heart disease has not significantly altered in

150 Valvular heart disease has recently become an increasing

151 lions of individuals with coronary artery or valvular heart disease have been given a new chance at l

152 k and benefit of mechanical interventions in valvular heart disease have been primarily described amo

153 Women with valvular heart disease have been underrepresented in man

154 Minimally invasive strategies to treat valvular heart disease have emerged over the past 2 deca

155 io 2.27; 95% CI, 1.03 to 5.04; P = .043) and valvular heart disease (hazard ratio 3.01; 95% CI, 1.05

156 2), atrial fibrillation HR 1.54 (1.36-1.73), valvular heart disease HR 1.23 (1.05-1.44), thromboembol

157 The 4 adventures include valvular heart disease, hypertrophic cardiomyopathy, hea

158 ORP VHD (EURObservational Research Programme Valvular Heart Disease) II survey.

159 ameters such as age, left atrial dilatation, valvular heart disease, impaired renal function, and ser

160 All valvular heart disease imparts a hemodynamic burden on t

161 fenfluramine (phen-fen) on the prevalence of valvular heart disease in 226 obese subjects enrolled in

162 We identified valvular heart disease in 24 women treated with fenflura

163 es were dilated cardiomyopathy in 119 (53%), valvular heart disease in 34 (15%), arrhythmogenic right

164 ary heart disease in 278 participants (52%), valvular heart disease in 42 (8%), hypertension in 140 (

165 Therapy for valvular heart disease in children has undergone tremend

166 on, history of congestive heart failure, and valvular heart disease in Cox proportional hazards model

167 sis have emerged as the most common forms of valvular heart disease in developed countries.

168 is the most common manifestation of acquired valvular heart disease in developed countries.

169 heart disease remains an infrequent cause of valvular heart disease in developed nations.

170 Because streptococcal M proteins produced valvular heart disease in Lewis rats and have been linke

171 fic aortic stenosis (CAS) is the most common valvular heart disease in older adults and has no effect

172 egurgitation (MR) is the most common type of valvular heart disease in patients over the age of 75 in

173 ent, progression and regression of carcinoid valvular heart disease in patients with carcinoid syndro

174 the pulmonic position in 2000, treatment for valvular heart disease in the outflow position has becom

175 contributing to altered profiles of acquired valvular heart disease in the past few decades include a

176 also be encountered in patients with severe valvular heart disease in the setting of CRS.

177 Aortic stenosis is the most common valvular heart disease in the United States.

178 Aortic stenosis is the most frequent valvular heart disease in the USA, and aortic valve repl

179 e (DAVD) has become the most common cause of valvular heart disease in the Western world, causing sig

180 se is increasing in importance as a cause of valvular heart disease in urban centers in the United St

181 tricuspid regurgitation are the most common valvular heart diseases in patients with heart failure a

182 c stenosis is perhaps the most common of all valvular heart diseases in the developed nations of the

183 uropean Society of Cardiology guidelines for valvular heart disease included changes in the definitio

184 However, most patients with valvular heart disease, including those undergoing trans

185 We focus on the most common primary valvular heart diseases, including calcific aortic steno

186 In the absence of pulmonary or valvular heart disease, increased RV uptake (i.e., RV pr

187 The mechanism of valvular heart disease involves an endochondral bone pro

188 Valvular heart disease is a common cause of morbidity an

189 Valvular heart disease is a condition with increasing pr

190 Valvular heart disease is a globally prevalent cause of

191 Valvular heart disease is a major cause of morbidity and

192 Transcatheter management of valvular heart disease is an emerging area of intense in

193 Valvular heart disease is an important contributor to ca

194 Valvular heart disease is common and its prevalence is r

195 Valvular heart disease is common in patients with system

196 The incidence of valvular heart disease is expected to increase over the

197 ontinued surveillance for significant aortic valvular heart disease is necessary.

198 Valvular heart disease is observed in approximately 2% o

199 Valvular heart disease is often associated with signific

200 Valvular heart disease is the most important cardiac man

201 "Degenerative" valvular heart disease is the primary cause of regurgita

202 ry artery disease (CAD) without pulmonary or valvular heart disease is unclear.

203 th observed in patients with hypertension or valvular heart diseases is called maladaptive or patholo

204 anaemia, chronic kidney disease, presence of valvular heart disease, left ventricular ejection fracti

205 hypertension, sex, left atrial enlargement, valvular heart disease, left ventricular ejection fracti

206 rol ratio, prevalent coronary heart disease, valvular heart disease, left ventricular hypertrophy, an

207 en high-risk surgical candidates with native valvular heart disease (mainly mitral with severe MAC) o

208 Pathologic left ventricular remodeling and valvular heart disease may contribute to the clinical pr

209 Defining sex-specific responses to valvular heart disease may improve disease recognition,

210 In patients with advanced valvular heart disease, mechanical approaches (both perc

211 sex) and clinical (diabetes, smoking status, valvular heart disease, medications, indications for cat

212 stress in the aortic valve, with functional valvular heart disease, mimicking the clinical syndrome.

213 CTRCEs included newly emerging arrhythmias, valvular heart diseases (moderate and more), myocardial

214 Patients with valvular heart disease often have left ventricular diast

215 7 ESC/EACTS Guidelines for the management of valvular heart disease on antithrombotic therapy in pati

216 No cases of valvular heart disease or pulmonary arterial hypertensio

217 s generally well tolerated, with no observed valvular heart disease or pulmonary arterial hypertensio

218 er, decreased ejection fraction, presence of valvular heart disease or the use of concomitant medicat

219 tory of coronary artery disease, MI, CHF, or valvular heart disease (OR 1.6 [95% CI 0.9-2.6]), revisi

220 ng conditions (for example, hypertension and valvular heart disease) or coronary artery disease.

221 ailure, such as pre-existing cardiomyopathy, valvular heart disease, or congenital heart disease.

222 or impact on the management of patients with valvular heart disease over the next several years.

223 Younger age (P = 0.004), valvular heart disease (P = 0.046), and the tricuspid an

224 Valvular heart disease, particularly aortic stenosis and

225 ered as the mechanism of VT in patients with valvular heart disease, particularly if the arrhythmia o

226 ts (N=114, 49%) compared with (ischemic and) valvular heart disease patients (N=26, 17%; P<0.001).

227 inflammation, not a result of the effects of valvular heart disease per se.

228 ry artery disease, congestive heart failure, valvular heart disease, pericardial disease, conduction

229 k score based on hypertension, age 75 years, valvular heart disease, peripheral vascular disease, obe

230 Intervention for valvular heart disease poses unique clinical challenges

231 , hypertension treatment, diabetes mellitus, valvular heart disease, prevalent myocardial infarction,

232 ask Force on the management of patients with valvular heart disease proscribe the use of bioprostheti

233 linically relevant 5-HT-related pathologies (valvular heart disease, pulmonary arterial hypertension)

234 disease (CAD), cardiomyopathies, significant valvular heart disease, pulmonary hypertension, and arrh

235 stive heart failure, ischemic heart disease, valvular heart disease, pulmonary hypertension, and cong

236 used on hemodynamic measurements to evaluate valvular heart disease, pulmonary hypertension, cardiomy

237 hts into hemodynamic changes associated with valvular heart diseases, pulmonary hypertension phenotyp

238 AS without coronary artery disease or other valvular heart disease, scheduled for surgical aortic va

239 serve as the basis for the development of a valvular heart disease screening program.

240 Future studies are needed to confirm whether valvular heart disease, specifically AS, may be an overl

241 ferences are observed across the spectrum of valvular heart disease, starting with pathophysiology an

242 METHODS AND We enrolled 335 consecutive valvular heart disease subjects who underwent echocardio

243 impact the treatment of coronary artery and valvular heart disease: SYNTAX, ART, and PARTNER.

244 , out-of-hospital cardiac arrest, left-sided valvular heart disease, the advocacy potential of these

245 rature beyond the pandemic are novel data on valvular heart disease, the increasing use of artificial

246 n investigated for its role in production of valvular heart disease, the most serious sequelae of gro

247 allenges inherent in translating research on valvular heart disease to viable molecular targets that

248 ease, chronic obstructive pulmonary disease, valvular heart disease, tobacco use, and alcohol abuse.

249 gh surgery was the mainstay of treatment for valvular heart disease, transcatheter valve therapies ha

250 The overall proportion of women enrolled in valvular heart disease trials was 41.1%, with no signifi

251 Valvular heart disease (VHD) and atrial fibrillation (AF

252 tudy was to evaluate the association between valvular heart disease (VHD) and maternal and fetal outc

253 Pregnancy in patients with valvular heart disease (VHD) continues to pose a challen

254 The occurrence of fenfluramine-associated valvular heart disease (VHD) has raised concerns that ot

255 Valvular heart disease (VHD) is a common condition that

256 Valvular heart disease (VHD) is a major contributor to l

257 Valvular heart disease (VHD) is a major global public he

258 Drug-induced valvular heart disease (VHD) is a serious side effect of

259 Valvular heart disease (VHD) is a significant source of

260 Background: Valvular heart disease (VHD) is an important cause of mo

261 Valvular heart disease (VHD) is becoming more prevalent

262 Valvular heart disease (VHD) is common and poses importa

263 with atrial fibrillation (AF) and coexisting valvular heart disease (VHD) is of substantial interest.

264 Valvular heart disease (VHD) is the next epidemic in the

265 art valves, significant mitral stenosis, and valvular heart disease (VHD) requiring intervention were

266 ege of Cardiology/American Heart Association valvular heart disease (VHD) stage prevalence, progressi

267 psed since the original Euro Heart Survey on valvular heart disease (VHD) was conducted with multiple

268 nt of pulmonary arterial hypertension (PAH), valvular heart disease (VHD), and related cardiopathies.

269 rminant of patient prognosis in degenerative valvular heart disease (VHD).

270 fore, may not be generalizable to those with valvular heart disease (VHD).

271 nd survival of patients with multiple native valvular heart disease (VHD).

272 tion of Q fever in patients with preexisting valvular heart disease (VHD).

273 or in mediating the heart valve fibroplasia [valvular heart disease (VHD)] and primary pulmonary hype

274 th ischemic heart disease [IHD], and 10 with valvular heart disease [VHD]).

275 Valvular heart disease was defined as history or baselin

276 essants fenfluramine and dexfenfluramine and valvular heart disease was first described in patients f

277 rditis, coronary artery disease, stroke, and valvular heart disease were also observed for multiple c

278 on for the evaluation of congenital or other valvular heart disease were excluded.

279 s who had primary cardiomyopathy and primary valvular heart disease were excluded.

280 jection fraction of less than 40%, or severe valvular heart disease were excluded.

281 ion fractions lower than 50%, or significant valvular heart disease were excluded.

282 diabetes, left ventricular hypertrophy, and valvular heart disease were predictive of increased risk

283 gy/American Heart Association guidelines for valvular heart disease were released to help guide the c

284 e for a variety of safety concerns including valvular heart disease which was the cause for the withd

285 amyloid deposits in patients with AF without valvular heart disease, which represents the most common

286 ith heart failure and identify patients with valvular heart disease who have myocardial decompensatio

287 LVEF may remain normal amongst patients with valvular heart disease who have significant myocardial d

288 , valve tissues from rheumatic patients with valvular heart disease who required valve replacement we

289 fraction < or =35%) and without significant valvular heart disease who underwent PET/FDG study at th

290 ed age, with chronic kidney disease, or with valvular heart disease will be discussed as well as the

291 Mitral valve prolapse (MVP) is a common valvular heart disease with a prevalence of >2% in the g

292 prevalent phenotype in patients affected by valvular heart disease with a well-recognized cluster of

293 Managing severe valvular heart disease with mechanical valve replacement